Lung Cancer
Volume 66, Issue 3 , Pages 282-286 , December 2009

Treatment of advanced non-small-cell lung cancer in the elderly

  • Cesare Gridelli

      Affiliations

    • Division of Medical Oncology, “S.G. Moscati” Hospital, Contrada Amoretta 83100, Avellino, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 0825 203574; fax: +39 0825 203556.
    • ,
  • Paolo Maione

      Affiliations

    • Division of Medical Oncology, “S.G. Moscati” Hospital, Contrada Amoretta 83100, Avellino, Italy
    • ,
  • Antonio Rossi

      Affiliations

    • Division of Medical Oncology, “S.G. Moscati” Hospital, Contrada Amoretta 83100, Avellino, Italy
    • ,
  • Marianna Luciana Ferrara

      Affiliations

    • Division of Medical Oncolgy, Second University of Naples, Italy
    • ,
  • Vincenzo Castaldo

      Affiliations

    • Direzione Sanitaria, “S.G. Moscati” Hospital, Avellino, Italy
    • ,
  • Giovanni Palazzolo

      Affiliations

    • Division of Medical Oncology, U.L.S.S.15, Cittadella, Padova, Italy
    • ,
  • Nicole Mazzeo

      Affiliations

    • Pharmacy Unit, “S.G. Moscati” Hospital, Avellino, Italy

Received 30 June 2009 ,Revised 27 July 2009 ,Accepted 6 August 2009.

References 

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108
  2. Ries LAG, Eisner MP, Kosary CL. SEER Cancer Statistics Review 1975–2000. Bethesda, MD: National Cancer Institute; 2003;[accessed on 30.06.2004] http://seer.cancer.gov/csr/1975_2000
  3. Owonikoko TK, Ragin CC, Belani CP, Oton AB, Gooding WE, Taioli E, et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol. 2007;25:5570–5577
  4. Wingo PA, Cardinez CJ, Landis SH, Greenlee RT, Ries LA, Anderson RN, et al. Long term trends in cancer mortality in the United States. Cancer. 2003;97:3133–3275
  5. Repetto L, Venturino A, Fratino L, Serraino D, Troisi G, Gianni W, et al. Geriatric oncology: a clinical approach to the older patient with cancer. Eur J Cancer. 2003;39:870–880
  6. Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montello MJ, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol. 2003;21:1383–1389
  7. Jatoi A, Hillman S, Stella P, Green E, Adjei A, Nair S, et al. Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the north Central Cancer Treatment Group. J Clin Oncol. 2005;23:9113–9119
  8. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004;22:330–353
  9. Gridelli C, Aapro M, Ardizzoni A, Calducci L, De Marinis F, Kelly K, et al. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol. 2005;23:3125–3137
  10. Elderly Lung Cancer Vinorelbine Italian Study (ELVIS) Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 1999;91:66–72
  11. Gridelli C, Cigolari S, Gallo C, Manzione L, Ianniello GP, Frontini L, et al. Activity and toxicity of gemcitabine and gemcitabine+vinorelbine in advanced non-small-cell lung cancer elderly patients. Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial. Lung Cancer. 2001;31:277–284
  12. Fidias P, Supko JG, Martins R, Boral A, Carey R, Grossbard M, et al. A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. Clin Cancer Res. 2001;7:3942–3949
  13. Kudoh S, Takeda K, Nakagawa K, Takada M, Katakami N, Matsui K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol. 2006;24:3657–3663
  14. Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst. 2003;95:362–372
  15. Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007;99:847–857
  16. Langer CJ, Vangel M, Schiller J. Age-specific subanalysis of ECOG 1594: fit elderly patients (70–80 yrs) with NSCLC do as well as younger pts (<70). Proc Am Soc Clin Oncol. 2003;22:639
  17. Kelly K, Giarritta S, Hayes S. Should older patients receive combination chemotherapy for advanced stage non-small cell lung cancer? An analysis of Southwest Oncology trials 9509 and 9308. Proc Am Soc Clin Oncol. 2001;20:329a
  18. Belani CP, Fossella FV. Phase III study (TAX 326) of docetaxel-cisplatin and docetaxel-carboplatin versus vinorelbine-cisplatin for the first-line treatment of advanced/metastatic non-small cell lung cancer: analyses in elderly patients. Lung Cancer. 2003;41(Suppl. 2):S18
  19. Lilenbaum RC, Herndon JE, List M, Desch C, Watson DM, Miller AA, et al. Single-agent versus combination chemotherapy in advanced non-small cell lung cancer: a CALGB randomized trial of efficacy, quality of life, and cost-effectiveness. J Clin Oncol. 2005;23:190–196
  20. Hensing TA, Peterman AH, Schell MJ, Lee JH, Socinski MA. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, stage IIIB or IV non small cell lung carcinoma treated with carboplatin and paclitaxel. Cancer. 2003;98:779–788
  21. Perrone F, Gallo C, Gridelli C. Re: Cisplatin-based therapy for elderly patients with advanced non-small cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst. 2002;94:1029–1031
  22. Feliu J, Martin G, Madronal C, Rodríguez-Jaráiz A, Castro J, Rodríguez A, et al. Combination of low-dose cisplatin and gemcitabine for treatment of elderly patients with advanced non small cell lung cancer. Cancer Chemother Pharmacol. 2003;52:247–252
  23. Ohe Y, Niho S, Kakinuma R, Kubota K, Ohmatsu H, Goto K, et al. A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients. Ann Oncol. 2004;15:45–50
  24. Gridelli C, Maione P, Illiano A, Piantedosi FV, Favaretto A, Bearz A, et al. Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies. J Clin Oncol. 2007;25:4663–4669
  25. Maestu I, Gómez-Aldaraví L, Torregrossa MD, Camps C, Llorca C, Bosch C, et al. Gemcitabine and low dose carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer. Lung Cancer. 2003;42:345–354
  26. Choi IS, Kim BS, Park SR, Lee SY, Kim DY, Kim JH, et al. Efficacy of modified regimen with attenuated doses of paclitaxel plus carboplatin combination chemotherapy in elderly and/or weak patients with advanced non small cell lung cancer. Lung Cancer. 2003;39:99–101
  27. Jackman D, Yeap B, Lindeman N, Fidias P, Rabin MS, Temel J, et al. Phase II clinical trial of chemotherapy-naive patients > or =70 years of age treated with erlotinib for advanced non-small cell lung cancer. An analysis of quality of life and symptom response. J Clin Oncol. 2007;25:760–766
  28. Chen Y, Tsai C, Shih J, Perng R, Whang-Peng J. Phase II randomized trial of erlotinib versus vinorelbine in chemotherapy-naive patients with advanced non-small-cell lung cancer aged ≥70 years in Taiwan. J Clin Oncol. 2009;27(18S):419s
  29. Crinò L, Cappuzzo F, Zatloukal P, Reck M, Pesek M, Thompson JC, et al. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol. 2008;26:4253–4260
  30. Wheatley-Price P, Ding K, Seymour L, Clark GM, Shepherd FA. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 2008;26:2350–2357
  31. Gridelli C, Morabito A, Gebbia V, Mencoboni M, Carrozza F, Viganò MG, et al. Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: the cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomised phase II trials. Lung Cancer. 2009;April 18 [Epub ahead of print]
  32. Herbst RS, Sun Y, Korfee S, Germonprè P, Saijo N, Zhou C, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZODIAC). J Clin Oncol. 2009;27(18S):807s
  33. Ramalingam SS, Dalhberg SE, Langer C, Gray R, Belani CP, Brahmer JR, et al. Outcome for elderly advanced non-small cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of the ECOG 4599 study. J Clin Oncol. 2008;26:60–65
  34. Jager E, Wu Y, Mezger J. Safety of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): M019390 (SAIL) study. Ann Oncol. 2008;19(Suppl. 8):viii93
  35. Leighl NB, Zatloukal P, Mezger J, Ramlau R, Archer V, Moore N, et al. Efficacy and safety of first-line bevacizumab and cisplatin/gemcitabine in elderly patients with advanced non-small cell lung cancer in the B017704 study (AVAiL). J Clin Oncol. 2009;27(18S):419s
  36. Gridelli C. Treatment of advanced non small-cell lung cancer in the elderly: from best supportive care to the combination of platin-based chemotherapy and targeted therapies. J Clin Oncol. 2008;26:13–15

PII: S0169-5002(09)00438-3

doi: 10.1016/j.lungcan.2009.08.006

Lung Cancer
Volume 66, Issue 3 , Pages 282-286 , December 2009

Article Tools